{"id":"rebif-new-formulation-prophylactic-ibuprofen","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection-site reactions (erythema, induration, pain)"},{"rate":"30-40","effect":"Flu-like symptoms (fever, chills, myalgia, fatigue)"},{"rate":"25-35","effect":"Headache"},{"rate":"10-20","effect":"Elevated liver enzymes"},{"rate":"5-15","effect":"Leukopenia"},{"rate":"5-10","effect":"Depression"}]},"_chembl":{"chemblId":"CHEMBL521","moleculeType":"Small molecule","molecularWeight":"206.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rebif is a recombinant interferon beta-1a that binds to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory responses that suppress pro-inflammatory Th1 and Th17 cell differentiation. The addition of prophylactic ibuprofen, a non-selective COX inhibitor, reduces prostaglandin-mediated inflammation and pain associated with interferon administration, potentially improving tolerability and adherence.","oneSentence":"Rebif (interferon beta-1a) activates interferon signaling pathways to modulate immune responses and reduce inflammation in the central nervous system, while prophylactic ibuprofen mitigates injection-site reactions and systemic inflammatory side effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:22.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Clinically isolated syndrome (CIS) with high risk of developing MS"}]},"trialDetails":[{"nctId":"NCT00619307","phase":"PHASE3","title":"Transition to Rebif New Formulation","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2007-07","conditions":"Relapsing Multiple Sclerosis","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rebif New Formulation + prophylactic Ibuprofen","genericName":"Rebif New Formulation + prophylactic Ibuprofen","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rebif New Formulation is used to treat Relapsing Multiple Sclerosis, as indicated by ClinicalTrials.gov. Prophylactic Ibuprofen, a cyclooxygenase inhibitor, is used in conjunction with Rebif New Formulation, as per ClinicalTrials.gov and ChEMBL.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}